Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Entrada Therapeutics Inc (NQ: TRDA )

15.04 +0.02 (+0.13%)
Streaming Delayed Price Updated: 3:10 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,225
Open 15.07
Bid (Size) 15.01 (2)
Ask (Size) 15.06 (3)
Prev. Close 15.02
Today's Range 15.04 - 15.38
52wk Range 10.62 - 18.44
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Entrada Therapeutics, Inc.
Via GlobeNewswire
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024
TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-0.86%
-0.86%
1 Month
+16.68%
+16.68%
3 Month
+13.60%
+13.60%
6 Month
+30.90%
+30.90%
1 Year
+17.96%
+17.96%

More News

Read More
Entrada Therapeutics Reports First Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Recap: Entrada Therapeutics Q4 Earnings
Via Benzinga
Insiders Buying America's Car-Mart And 2 Other Stocks
Via Benzinga
Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Promotes Nathan J. Dowden to President
From Entrada Therapeutics, Inc.
Via GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.